Brainsway Ltd (IL:BWAY)
TASE:BWAY
Want to see IL:BWAY full AI Analyst Report?
BWAY Stock Chart & Stats
3718.00
0.01(0.06%)
At close: 4:00 PM EST
3718.00
0.01(0.06%)
Day’s Range― - ―
52-Week Range1,498.00 - 5,026.00
Previous CloseN/A
Volume32.24K
Average Volume (3M)85.46K
Market Cap
₪1.90B
Enterprise Value575.91M
Total Cash (Recent Filing)₪69.13M
Total Debt (Recent Filing)₪6.82M
Price to Earnings (P/E)71.4
Beta0.06
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)23.90
Shares Outstanding40,033,028
10 Day Avg. Volume88,081
30 Day Avg. Volume85,462
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)5.11
Price to Sales (P/S)6.62
P/FCF Ratio21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ScalingMulti-year revenue growth to $56.5M reflects durable market adoption of Deep TMS. A larger installed base combined with mid-70% gross margins supports recurring consumables and service revenue, enabling sustainable operating leverage and predictable top-line contribution over coming months.
Improved Profitability & Cash GenerationThe shift to positive net income and materially higher operating and free cash flow signals sustainable internal funding for commercialization, service expansion and R&D. Strong cash generation reduces reliance on external financing and supports reinvestment over the medium term.
Conservative Balance SheetHistorically low leverage and rising equity provide capital flexibility to fund installations, training and service networks without heavy borrowing. Modest debt limits solvency risk and gives resilience to absorb reimbursement or demand fluctuations over the next several months.
Bears Say
Historical Cash-Flow VolatilityPrior years of negative free cash flow indicate execution and cyclical risk: the recent step-up in cash generation may not be stable if utilization or placements weaken. Reversion would constrain capex, service and commercial investments, impairing longer-term growth plans.
Growth DecelerationA notable slowdown in top-line growth reduces the tempo for installed-base expansion and recurring revenues. Slower growth can delay margin expansion and makes the business more sensitive to competitive, reimbursement or execution setbacks over the medium term.
Dependence On Reimbursement & AdoptionDemand and recurring revenue depend materially on payer reimbursement, provider utilization and regulatory approvals. These external, slow-moving factors create structural uncertainty: adverse policy shifts or slow clinical uptake can meaningfully reduce system placements and recurring revenue.
Brainsway News
BWAY FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was 1498.00 and its highest was 5026.00 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is ₪1.90B.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is May 13, 2026 which is in 12 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on Mar 11, 2026. The company reported 23.9 earnings per share for the quarter, beating the consensus estimate of N/A by 23.9.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Overvalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 40,033,028 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of 23.9 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.1%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in IL:BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brainsway Ltd
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
BWAY Company Deck
BWAY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in revenue and system shipments, successful strategic investments, and improved financial guidance. However, there were increased operating expenses and delays in FDA clearance for a strategic partner's product. Overall, the positives significantly outweigh the negatives.View all IL:BWAY earnings summaries